May 13, 2024 – Page 10 – Goldea Capital

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024. “Over the past month we have made considerable progress toward initiating our planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa. Our experienced team has been working closely with subject matter experts on trial enabling activities, and we plan to have the trial underway this year,” said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. “Our main focus remains on the initiation of the Phase 2 trial in hidradenitis...

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

– Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Preliminary Phase 2 results for VP-315 in the treatment of basal cell carcinoma (BCC) expected in the second quarter of 2024 – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., May 13, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2024. “The first quarter of 2024 marked a period of significant accomplishments across our business, as we continued to expand utilization of YCANTH, received a permanent J-Code from...

Spectral Medical Announces First Quarter Results and Provides Corporate Update

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

Tigris Trial Enrollment Reaches 106 Patients Bought Deal Financing Expected to Fund Completion of Tigris Trial Enrollment TORONTO, May 13, 2024 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update. Spectral has continued its significant progress throughout the first quarter of 2024 both clinically and operationally and year-to-date enrolled 25 patients for a total of 106 patients out of the 150 total patients target. The Company is focused on the final push to fully enroll and finish the Tigris trial and believes that the continued onboarding of new Tigris sites since the fourth quarter of 2023...

Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results. Clinical Updates AD Phase II/III Study On April 29, Annovis announced statistically significant Phase II/III data in patients with early Alzheimer’s disease (AD). Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD; Improvement in cognition measured by ADAS-Cog 11 at three months was 3.3 points as compared to 0.3 for placebo, consistent with previous Phase II AD/PD and Discovery studies; Plasma Tau protein levels were reduced, consistent with previous Phase...

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

Written by Customer Service on May 13, 2024. Posted in Public Companies.

CUPERTINO, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present new efficacy data on brilaroxazine in an animal model of idiopathic pulmonary fibrosis as part of a late-breaking poster presentation at the 2024 American Thoracic Society (ATS) International Conference, to be held in San Diego, CA, May 17-22, 2024. Details for the poster presentation can be found below: Title: Effectiveness of brilaroxazine on functional and underlying pathological inflammation and fibrosis parameters...

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Written by Customer Service on May 13, 2024. Posted in Public Companies.

Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024 Ongoing progress of Investigational New Drug (IND) enabling studies in systemic lupus erythematosus (SLE) program for GRI-0803 with IND filing expected in H2 2024 LA JOLLA, CA, May 13, 2024 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the first quarter ended March 31, 2024 and provided a corporate update. “We continue to execute on both the clinical and corporate fronts. Our team is working diligently...

Verde Bio and SensaSure Technologies Complete Merger to Create Premier Mineral Acquisitions Company

Written by Customer Service on May 13, 2024. Posted in Mergers And Acquisitions.

The combined company will focus on the acquisition and management of oil and gas of minerals and royalties Combined company renamed Formation Minerals, Inc. and will be led by Mr. Scott Cox as President and Chief Executive Officer Transaction expected to deliver sustainable, long-term value to stockholders JACKSBORO, TX., May 13, 2024 (GLOBE NEWSWIRE) — SensaSure Technologies Inc. (OTCQB: SSTC) (“SensaSure”) and Verde Bio Holdings, Inc. (OTC: VBHI) (“Verde” or the “Company”), a growing oil and gas company with a focus on the acquisition and management of oil and gas minerals and royalties, today announced the closing of the previously announced merger (the “Merger”) of Formation Minerals, Inc., a wholly owned subsidiary of SensaSure, with and into Verde, to create a premier company focused on the acquisition and management of oil...

Reneo Pharmaceuticals and OnKure Announce Proposed Merger

Written by Customer Service on May 13, 2024. Posted in Mergers And Acquisitions.

Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide funding through multiple clinical milestones and runway into fourth quarter of 2026 IRVINE, Calif., and BOULDER, Colo., May 13, 2024 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic...

Iterum Therapeutics Reports First Quarter 2024 Financial Results

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

–-NDA Resubmitted; FDA Action Expected in Early Q4 24– –-Cash Runway into 2025, including through Potential FDA Approval– –Company to Host Conference Call Today at 8:30 a.m. EDT– DUBLIN, Ireland and CHICAGO, May 13, 2024 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), (Iterum) a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2024. “We are pleased to have recently resubmitted our new drug application (NDA) for oral sulopenem just three months after reporting positive topline data from our REASSURE trial in January 2024,” said Corey Fishman, Iterum’s Chief Executive...

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week proof-of-concept data from Part A of the trial expected in 2H 2025 First participant dosed in Phase 1 healthy volunteer clinical trial of APG808, a subcutaneous half-life extended monoclonal antibody targeting IL-4Rα, for the treatment of chronic obstructive pulmonary disease and other inflammatory diseases with interim Phase 1 data expected in 2H 2024 Nominated development candidate for APG990, a subcutaneous half-life extended monoclonal antibody targeting OX40L, with a Phase 1 trial in healthy volunteers expected to initiate in 2H 2024 $816 million cash, cash equivalents and marketable securities with runway into 2028 SAN FRANCISCO and WALTHAM, Mass.,...

Day: May 13, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice